Bleichmar Fonti & Auld LLP has launched a securities fraud investigation into IBM following a 25 percent stock drop that erased $68 billion in market value on July 14. The probe examines whether IBM misled investors about IBM Z mainframe performance and deal slippages. Multiple law firms are conducting parallel investigations.
IBM's 25 percent stock drop erased $68 billion in market value, triggering a securities fraud investigation by Bleichmar Fonti & Auld LLP.
"Here's the good news: about 40 percent of them have already closed in three to four weeks," CEO Arvind Krishna said on CNBC's "Mad Money," referring to deferred customer deals. "That's a good signal that it is a deferral, not a destruction."
The probe, announced Aug. 17, examines whether IBM misled investors about IBM Z mainframe performance and deal slippages. On July 14, IBM reported that numerous large deals failed to close on expected timelines, primarily impacting Transaction Processing revenues. The stock fell over $75 per share in intraday trading to close at $217.07. IBM Z revenue had risen 51 percent in Q1 FY26, with executives describing a "record start" for the z17 product.
The investigation runs parallel to separate probes by Pomerantz LLP, announced Aug. 6, and by Glancy Prongay Wolke & Rotter LLP and Levi & Korsinsky LLP. IBM posted Q2 revenue of $17.16 billion, beating the consensus estimate of $16.86 billion, with adjusted earnings of $2.93 per share versus expectations of $2.86. Shares closed at $223.65 on Friday, up 0.86 percent.
The gap between IBM's April guidance and July actuals highlights the volatility in its enterprise software cycles. While generative AI accounted for approximately 50 percent of signings in Q2 FY26, it failed to offset the decline in traditional transaction processing revenues. Total revenue growth came in at 1 percent versus the 5-plus percent projected in April, while infrastructure revenue swung from plus 15 percent in Q1 to minus 7 percent.
The concentration risk within IBM's Transaction Processing segment remains a critical vulnerability. Management expects two-thirds to three-quarters of slipped deals to close within six months, but the immediate market reaction reflects skepticism about the reliability of such projections. The investigation seeks to determine if these risks were adequately disclosed before the stock price correction.
The probe could lead to legal costs and potential financial penalties for IBM. Investors who purchased shares during the relevant period are urged to contact BFA Law, with representation on a contingency fee basis. The next event to watch is any formal complaint filing or class action certification, which would test the strength of the claims against IBM's disclosure practices.
This article is for informational purposes only and does not constitute investment advice.
